Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.

Kei A, Liberopoulos EN, Mikhailidis DP, Elisaf M.

Int J Clin Pract. 2013 May;67(5):412-9. doi: 10.1111/ijcp.12098. Epub 2013 Mar 20.

PMID:
23510018
2.
3.

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.

Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A.

Eur J Clin Invest. 2013 Jul;43(7):698-707. doi: 10.1111/eci.12095. Epub 2013 Apr 20.

PMID:
23600368
4.

Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.

Kei A, Liberopoulos E, Tellis C, Elisaf M, Tselepis A.

Lipids. 2013 Oct;48(10):957-65. doi: 10.1007/s11745-013-3826-y. Epub 2013 Aug 15.

PMID:
23949918
5.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
6.

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.

Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS.

Int J Clin Pract. 2012 Sep;66(9):843-53. doi: 10.1111/j.1742-1241.2012.02972.x.

PMID:
22897461
7.

Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia.

Kei A, Liberopoulos E, Elisaf M.

World J Diabetes. 2013 Dec 15;4(6):365-71. doi: 10.4239/wjd.v4.i6.365.

8.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.

J Clin Lipidol. 2012 Nov-Dec;6(6):534-44. doi: 10.1016/j.jacl.2012.02.002. Epub 2012 Feb 8.

PMID:
23312049
9.
10.

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.

Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD.

Prev Cardiol. 2004 Fall;7(4):176-81.

11.

Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.

Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M.

J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):382-6. doi: 10.1177/1074248412439470. Epub 2012 Mar 19.

PMID:
22431864
12.

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000.

PMID:
19995098
13.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
14.

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):427-32. doi: 10.1161/ATVBAHA.113.302019. Epub 2013 Nov 27.

15.

Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA.

Clin Cardiol. 2010 Oct;33(10):609-19. doi: 10.1002/clc.20830.

16.

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D.

Int J Clin Pract. 2010 May;64(6):727-38. doi: 10.1111/j.1742-1241.2010.02370.x.

PMID:
20518948
17.

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.

Cardiovasc Drugs Ther. 2010 Dec;24(5-6):421-8. doi: 10.1007/s10557-010-6266-4.

PMID:
20953684
18.

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD.

Expert Opin Pharmacother. 2011 Dec;12(17):2605-11. doi: 10.1517/14656566.2011.591383. Epub 2011 Jun 29.

PMID:
21714585
19.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.

Clin Ther. 2013 Aug;35(8):1186-98. doi: 10.1016/j.clinthera.2013.06.013. Epub 2013 Jul 26. Erratum in: Clin Ther. 2013 Nov;35(11):1862.

PMID:
23891363
20.

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.

Diabetes Res Clin Pract. 2004 May;64(2):137-51.

PMID:
15063607

Supplemental Content

Support Center